For research use only. Not for therapeutic Use.
AEF0117 is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 plays an important role in Cannabis use disorder (CUD)[1].
| Catalog Number | I040535 |
| CAS Number | 1610878-71-1 |
| Synonyms | 1-[(3S,8S,9S,10R,13S,14S,17S)-3-[(4-methoxyphenyl)methoxy]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone |
| Molecular Formula | C29H40O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C29H40O3/c1-19(30)25-11-12-26-24-10-7-21-17-23(32-18-20-5-8-22(31-4)9-6-20)13-15-28(21,2)27(24)14-16-29(25,26)3/h5-9,23-27H,10-18H2,1-4H3/t23-,24-,25+,26-,27-,28-,29+/m0/s1 |
| InChIKey | AAZPIQPULVRHOW-SFKJMYEFSA-N |
| SMILES | CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OCC5=CC=C(C=C5)OC)C)C |
| Reference | [1]. Margaret Haney, et al. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nat Med. 2023 Jun;29(6):1487-1499. |
